Treatment with azacitidine (AZA), a demethylating agent, prolonged overall survival (OS) vs conventional care in patients with higher-risk myelodysplastic syndromes (MDS). As median survival with monotherapy is <2 years, novel agents are needed to improve outcomes. This phase 1b/2b trial (n=113) was designed to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of panobinostat (PAN) + AZA (phase 1b) and evaluate early efficacy and safety of PAN+AZA vs AZA monotherapy (phase 2b) in patients with higher-risk MDS, chronic myelomonocytic leukemia, or oligoblastic acute myeloid leukemia with <30% blasts. The MTD was not reached; the RP2D was PAN 30 mg plus AZA 75 mg/m(2). More patients receiving PAN+AZA achieved a composite complete response ([CR] + morphologic CR with incomplete blood count + bone marrow CR (27.5% [95% CI, 14.6-43.9%]) vs AZA (14.3% [5.4-28.5%]). However, no significant difference was observed in the 1-year OS rate (PAN+AZA, 60% [50-80%]; AZA, 70% [50-80%]) or time to progression (PAN+AZA, 70% [40-90%]; AZA, 70% [40-80%]). More grade 3/4 adverse events (97.4 vs 81.0%) and on-treatment deaths (13.2 vs 4.8%) occurred with PAN+AZA. Further dose or schedule optimization may improve the risk/benefit profile of this regimen.Leukemia accepted article preview online, 26 May 2017. doi:10.1038/leu.2017.159.
Pharmacology, Toxicology and Pharmaceutical Science
4
6%
Agricultural and Biological Sciences
4
6%
Nursing and Health Professions
3
5%
Other
2
3%
Unknown
26
42%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 June 2017.
All research outputs
#18,827,930
of 24,003,070 outputs
Outputs from Leukemia
#4,566
of 5,213 outputs
Outputs of similar age
#228,640
of 316,642 outputs
Outputs of similar age from Leukemia
#68
of 88 outputs
Altmetric has tracked 24,003,070 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 5,213 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.3. This one is in the 10th percentile – i.e., 10% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 316,642 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 23rd percentile – i.e., 23% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 88 others from the same source and published within six weeks on either side of this one. This one is in the 18th percentile – i.e., 18% of its contemporaries scored the same or lower than it.
